The biotech company’s pivot into digital assets marks one of the largest treasury financings to date, underscoring growing institutional demand for tokenized finance.
Biotech company Tharimmune has raised $540 million in private funding to launch a crypto treasury strategy and acquire Canton Coin (CC), the native token of the Canton Network.
The private offering, among the largest digital asset financings to date, was led by DRW and Liberty City Ventures, with participation from ARK Invest, Polychain Capital, Kraken, and other institutional investors. The round values Tharimmune’s shares at $3.075 each.
Tharimmune said the funds will be used to purchase CC tokens, support general operations, and expand its role within the Canton ecosystem. The company also plans to become a Super Validator, operating additional nodes to earn token rewards and strengthen network performance.
